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Leone, Liberia and Guinea. The NLFSFN was formed in 2007
to meet the need for a structured and sustained response
to the control of the epidemic in Nigeria. We describe the
spread of the epidemic from 2001-2007, the change in its
seasonality, the rise in prevalence and the decline in case
fatality rate (CFR) among hospital patients.
Methods: Review of surveillance data at the Federal Min-
istry of Health and the Institute of Lassa Fever Research and
Control, ISTH, Irrua and review of the case load and out-
come of suspected LF at the ISTH. The diagnosis of LF was
based on deﬁned criteria.
Results: From 2001 — 2006, 1-3 (average 1.7 or 5%) of
the 36 States and the Federal Capital Territory reported LF
compared to 7-12 (average 9.7) States in 2007-2009 (OR (95%
CI) = 0.26 (0.13, 0.53), p < 0.01). Suspected LF constituted
0.53% of 41,440 admissions in 2001-06 compared to 2.16%
of 35,484 admissions in 2007-09 (RR (95% CI) = 1.7 (1.64,
1.76), p « 0.001). Ninety (76%) of 118 cases of suspected
LF managed at the ISTH in 2001-04 were seen in January
to March compared to 49/103 (48%) in 2004-05 (RR (95%
CI) = 1.9 (1.32,
2.62), p « 0.001) and 271/765 (35%) in 2007-09 (RR (95%
CI) = 1.56 (1.09, 2.24), p = 0.02 for 2007-09 versus 2005-06).
CFR from suspected LF was 97/221 (43.9%) in 2001-06 versus
102/768 (13.3%) in 2007-09 (RR (95% CI) = 0.61 (0.53, 0.7), p
«0.001). Overall, the diagnosis of LF was conﬁrmed in 16-25%
of cases of suspected LF in 2008-09. In each of the 3 Sena-
torial Districts in Edo State, the prevalence of suspected LF
as seen at the ISTH increased by >149% from 2008 — 2009
while that of conﬁrmed LF increased by >73%.
Conclusion: Both awareness of the epidemic and the
index of suspicion in clinical diagnosis have increased as
immediate gains from the LF control activities of the
NLFSFN. The seasonality of LF has changed while the preva-
lence in Nigeria may have increased, perhaps in part due
to the increased awareness and index of suspicion. Assis-
tance of the international community is required to scale
up the control initiatives, particularly with regard to capac-
ity building in surveillance, laboratory diagnosis and case
management.
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Background: The complexity of the therapeutic approach
of the immunocompromised patients is determinate by
the capacity of their immunoresponse corresponding with
the arising infection. Among the patients with shingles
with a comorbide immunodeﬁciency syndrome such as pri-
mary hypogamaglobulinaemia or secondary lymphopenia as
a result of a long lasting immunosuppressive therapeutic
treatment that is even more complex, due to threatening
viral generalization, including visceral generalization of the
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llness as well as dermal and pulmonary bacterial superin-
ection.
Methods: During the 6 year long period, 20 immuno-
ompromised patients with shingles were hospitalized and
ealed in our department. Dermal eruptions were spreaded
n several dermatoms, in 8 patients with dermal general-
zation. Visceral generalization appeared in 4 cases with all
onsecutive disorders. Diagnostic criteria, including com-
lete blood count (CBC), sedimentation, chemistry proﬁle
f renal and liver function tests, bacteriological (inducted
xpectorated) sputum sample testing, blood culture, pleural
uid analysis, chest xray and tomography, were determin-
ng moments in the diagnostic procedure and therapeutic
reatment.
Results: Appearance of the Acyclovir (for oral or i.v.
pplication), as a systemic virostatic with high efﬁciency,
ramatically changed the evolution of the illness in this
roup of patients, their clinical symptomatology and expres-
ion, with the drastic reduction of the sequels and the
pilogue of the illness. Due to the effect of viral repli-
ation blocking, its efﬁciency is evident, especially if it
s applicated within the ﬁrst 3 days of the illness (24-
8-72 hours after the appearance of the ﬁrst symptoms)
t the period of the most intense viral replication. These
atients were parenterally/peroral treated with Acyclovir
Virolex) and antibiotics - Penicillines, II and III generation
ephalosporines, Aminoglycosides, Macrolides, Quinolones,
lindamycin, Lincomycin, Co-trimoxazol.
Conclusion: All patients showed satisfying resolve of the
ermal lesions, resolution of the pulmonary inﬂammation
nd correction of the chemistry proﬁle of renal and liver
unction as well as abrogation of all clinical symptoms and
ubjective difﬁculties. Is it necessary to point out the impor-
ance of the substitutional and symptomatic therapy that
ave to be implemented simultaneously with antiviral and
ntibiotic therapy, as the only possible and satisfactory way
f treatment of this group of patients along with necessary
ttention and care.
oi:10.1016/j.ijid.2010.02.678
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eculiar case of herpetic viral encephalitis
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Background: Herpetic viral encephalitis is a severe
isease, especially in neonates and immunocompromised
osts. HSE with HSV 2 appears more frequently in persons
ounger than 20 and older than 50. Immunossupresion may
e the cause of herpes simplex viral encephalitis.
Methods: The case presentation is supported by the infor-
ation found in this patient’s ﬁles from three medical
ervices where he was admitted: Clinic of Internal Medicine,
eurosurgery, and ﬁnally Clinic of Infectious Diseases of the
niversity of Oradea.
Results: A 16 years old rural male patient, presented
tarting with September 2009 headaches, night sweating,
ack of appetite, vomiting, abdominal pain, diarrhea and
